基因突變：泰格莎三年努力 改善手術後肺癌患者存活 Three-Year Effort Improves Survival for Post-Surgery Lung Cancer

《基因突變：泰格莎三年努力 改善手術後肺癌患者存活》這項研究揭示了一個關鍵發現，泰格莎的治療努力延長了手術後肺癌患者的生存期。這個發現突顯了基因突變在治療中的重要性，為改善肺癌患者的生存帶來新的希望。研究結果不僅標誌著醫學界的一大突破，也為未來的肺癌治療提供了寶貴的指引。"

The study 'Gene Mutation: Three-Year Effort Improves Survival for Post-Surgery Lung Cancer Patients' reveals a pivotal finding: Osimertinib treatment efforts have extended the survival period of post-surgery lung cancer patients. This discovery underscores the significance of gene mutations in treatment, offering new hope for enhancing the survival rates of lung cancer patients. The research results not only mark a significant breakthrough in the medical field but also provide valuable insights for future lung cancer treatments.

腫瘤科醫師的生活點滴
臉書facebook：
https://m.facebook.com/profile.php/?id=100063644122566
Instagram：
https://instagram.com/chiaoenpeter?igshid=OGQ5ZDc2ODk2ZA==
加入頻道會員：
https://www.youtube.com/channel/UCBvUlnJq3TpnGtbV6fdnl2A/join
分享會員專屬影片：
https://www.youtube.com/playlist?list=UUMOBvUlnJq3TpnGtbV6fdnl2A